← Back to Clinical Trials
Recruiting NCT07142668

NCT07142668 Effects of Tax Proposals and Cigarette Availability on Tobacco Purchasing

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07142668
Status Recruiting
Phase
Sponsor Virginia Polytechnic Institute and State University
Condition Cigarette Smoking
Study Type INTERVENTIONAL
Enrollment 316 participants
Start Date 2025-08-14
Primary Completion 2026-09-15

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Harm Reduction Tax - Normal Nicotine Cigarettes AvailableHarm Reduction Tax - Normal Nicotine Cigarettes Not AvailableModified Risk Tobacco Product Tax - Normal Nicotine Cigarettes Available

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 316 participants in total. It began in 2025-08-14 with a primary completion date of 2026-09-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will investigate the effects of normal-nicotine versus low-nicotine cigarette availability in the context of four tax proposals (Tobacco Parity, Nicotine-Content, Harm-Reduction, and Modified Risk Tobacco Product-based taxes) on tobacco product purchasing patterns in a virtual marketplace.

Eligibility Criteria

Inclusion Criteria: * provide informed consent * provide a breath carbon monoxide sample ≥ 8 ppm, * be at least 21 years of age (the legal age to purchase tobacco), * smoke at least 10 cigarettes daily, and * use other tobacco products less than weekly. Exclusion Criteria: * report uncontrolled physical or mental health conditions (e.g., uncontrolled diabetes, high blood pressure, major depressive disorder, etc.), * use of smoking cessation medications (e.g., nicotine replacement, bupropion, varenicline) in the past 30 days, * report concrete, immediate plans to alter/quit using their usual tobacco products in the next 30 days, * be pregnant or lactating, or * have plans to move out of the area during the experiment.

Contact & Investigator

Central Contact

Kirstin Gatchalian

✉ kmgatch@vtc.vt.edu

📞 540-526-2071

Principal Investigator

Jeff S Stein, Ph.D.

PRINCIPAL INVESTIGATOR

Fralin Biomedical Research Institute at VTC

Frequently Asked Questions

Who can join the NCT07142668 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, studying Cigarette Smoking. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07142668 currently recruiting?

Yes, NCT07142668 is actively recruiting participants. Contact the research team at kmgatch@vtc.vt.edu for enrollment information.

Where is the NCT07142668 trial being conducted?

This trial is being conducted at Buffalo, United States, Roanoke, United States.

Who is sponsoring the NCT07142668 clinical trial?

NCT07142668 is sponsored by Virginia Polytechnic Institute and State University. The principal investigator is Jeff S Stein, Ph.D. at Fralin Biomedical Research Institute at VTC. The trial plans to enroll 316 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology